Current Report Filing (8-k)
January 10 2023 - 06:03AM
Edgar (US Regulatory)
false 0001590877 0001590877 2023-01-09
2023-01-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 09,
2023
REGENXBIO Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Delaware |
|
001-37553 |
|
47-1851754 |
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
9804 Medical Center Drive
Rockville, Maryland
|
|
|
|
20850 |
|
(Address of Principal Executive
Offices) |
|
|
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (240)
552-8181
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, par value $0.0001 per share |
|
RGNX |
|
The
NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
|
Management Changes
On January 9, 2023, REGENXBIO Inc. (the “Company”) announced
that Curran M. Simpson has been named Chief Operating Officer,
effective immediately. Mr. Simpson, age 61, previously served
as the Company’s Senior Vice President, Chief Operations and
Technology Officer and has been a member of the Company’s senior
management team since August 2015.
Information about Mr. Simpson, his service with the Company,
his business experience and his compensation was disclosed in the
Company’s definitive proxy statement for the Company’s 2022 Annual
Meeting of Shareholders, which was filed on April 7, 2022.
A copy of the Company’s press release announcing Mr. Simpson’s
promotion is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
| Item 9.01. |
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
| Date: January 10, 2023 |
|
|
|
By: |
|
/s/ Patrick J. Christmas II
|
|
|
|
|
|
|
Patrick J. Christmas II |
|
|
|
|
|
|
Executive Vice President, Chief
Legal Officer |
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2023 to Mar 2023
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2022 to Mar 2023
